USP44 and cancer: A lack of Treg‐specific USP44 expression also significantly stunted progression of s.c. B16F10 melanomas and EL4 thymomas (Fig 7B and C)—results both supporting a pro‐tumor role for this DUB and compatible with a significant contribution to pathological tolerance in the cancer setting.